Literature DB >> 26742874

Prevalence and risk factors of vision impairment among children of employees of Telecom, Italy.

Carlo Nucci1, Vincenza Cofini2, Raffaele Mancino1, Federico Ricci1, Alessio Martucci1, Maria Rosita Cecilia2, Vincenzo Ciciarelli3, Francesca Zazzara2, Claudio Cedrone1, Ferdinando di Orio2.   

Abstract

PURPOSE: To define the prevalence, causes, and risk factors of vision impairment (VI) in children.
METHODS: In this study, relatives of Association for Supplemental Health Insurance to the Employees of Telecom members aged 5-16 years were examined in all Italian regions. A standardized record card was used to collect data on medical history; keratometry; objective refraction; uncorrected, presenting, and best-corrected visual acuity (VA); examination of the pupils, adnexa, and anterior segment; direct ophthalmoscopy; posterior segment and fundus examination; and assessment for ocular pathology. Binocular and monocular VI were defined by a VA <5/10 (or <20/40).
RESULTS: The campaign included 17,508 children, 12,798 of whom (73.1%) were examined (and 12,740 on whom all VA data were gathered). The prevalence of uncorrected, presenting, and best-corrected VI in the better eye was 9.0%, 2.51%, and 0.10%, respectively. The following variables were associated with presenting VI: age 10-16 years, family history of myopia, female sex, family history of keratoconus, and hypertension. Myopia is the main cause of VI (82.6%). A total of 96% of children with presenting VI had correctable VI.
CONCLUSIONS: Correctable VI because of myopia is an important public health problem in school-age children in Italy.

Entities:  

Mesh:

Year:  2015        PMID: 26742874     DOI: 10.5301/ejo.5000733

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  1 in total

1.  Vision screening in children: Is 7-9 years of age a threshold for visual impairment?

Authors:  Yusuf Haydar Ertekin; Murat Tekin; Aysegul Uludag; Sedat Arikan; Erkan Melih Sahin
Journal:  Pak J Med Sci       Date:  2016 Sep-Oct       Impact factor: 1.088

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.